Notice Pursuant to the National Cooperative Research and Production Act of 1993-America's DataHub Consortium, 75567 [2024-20968]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 179 / Monday, September 16, 2024 / Notices
Trade and Investment Queensland, San
Francisco, CA; TruGenomix Health,
Inc., dba Polaris Genomics,
Gaithersburg, MD; Unveil LLC,
Cincinnati, OH; Ursus Medical Designs
LLC, Pittsburgh, PA; and Vaxxas Pty,
Ltd., Hamilton, AUSTRALIA, have been
added as parties to this venture.
Also, ImmersiveTouch, Inc., Chicago,
IL; Neuromersive, Inc., Fort Worth, TX;
Precisio Biotix Technologies, Dover, DE;
and Sepsis Scout, Inc., San Francisco,
CA, have withdrawn as parties to this
venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and MTEC
intends to file additional written
notifications disclosing all changes in
membership.
On May 9, 2014, MTEC filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on June 9, 2014(79 FR 32999).
The last notification was filed with
the Department on April 2, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on June 21, 2024(89 FR 52090).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
OH; Data Point LLC, Orange, NJ; Data
Products LLC, Chicago, IL; Generative
Medical, Inc., Palo Alto, CA; K8R
Applications, Inc. dba Future Perfect
Engineering, Seattle, WA; Node.Digital,
Leesburg, VA; Omnicom Consulting
Group, Inc., Tarrytown, NY; Polaron
Technologies, Inc., Miamisburg, OH;
Prism Lab at Cornell University, Ithaca,
NY; and Vistra Communications LLC,
Lutz, FL, have been added as parties to
this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and ADC intends
to file additional written notifications
disclosing all changes in membership.
On November 11, 2021, ADC filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on December 22, 2021 (86 FR
72628).
The last notification was filed with
the Department on April 4, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on June 21, 2024 (89 FR 52092).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2024–20968 Filed 9–13–24; 8:45 am]
BILLING CODE P
[FR Doc. 2024–20967 Filed 9–13–24; 8:45 am]
BILLING CODE P
lotter on DSK11XQN23PROD with NOTICES1
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Antitrust Division
[Docket No. 23–31]
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—America’s DataHub
Consortium
Mary A. Vreeke, M.D.; Decision and
Order
Notice is hereby given that, on June
28, 2024, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), America’s DataHub
Consortium (‘‘ADC’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, ADACEN FEDERAL LLC,
Albuquerque, NM; AT Worthy
Technology, Fairfax, VA; Brightquery,
Inc., Irvine, CA; Careplots, Inc.,
Malvern, PA; CAS a division of
American Chemical Society, Columbus,
VerDate Sep<11>2014
17:23 Sep 13, 2024
Jkt 262001
On February 13, 2023, the Drug
Enforcement Administration (DEA or
Government) issued an Order to Show
Cause (OSC) to Mary A. Vreeke, M.D.
(Respondent), of Oxnard, CA. OSC, at 1,
5. The OSC proposed the revocation of
Respondent’s DEA Certificate of
Registration (Registration) No.
FV3660037, alleging that Respondent’s
continued registration is inconsistent
with the public interest. Id. at 1 (citing
21 U.S.C. 823(g)(1), 824(a)(4)).
A hearing was held before DEA
Administrative Law Judge Paul E.
Soeffing (the ALJ), who, on October 19,
2023, issued his Recommended Rulings,
Findings of Fact, Conclusions of Law,
and Decision (Recommended Decision
or RD). The RD recommended that
Respondent’s Registration be suspended
for six months, and then reinstated with
restrictions to ensure that Respondent
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
75567
remains sober and continues with her
current treatment program.1 RD, at 27.
Neither party filed Exceptions to the RD.
Having reviewed the entire record, the
Agency adopts and hereby incorporates
by reference the ALJ’s credibility
findings,2 findings of fact, and
conclusions of law, and clarifies and
expands upon portions thereof herein.
However, the Agency has determined
that revocation is the appropriate
sanction based on the egregiousness of
Respondent’s conduct, her recidivism,
and the Agency’s interests in deterring
intentional violations of the Controlled
Substances Act (CSA).
I. Findings of Fact
Respondent is an anesthesiologist
currently practicing at St. John’s
Hospital in Oxnard, California.
Respondent testified that she has a
substance abuse disorder that began
with abusing alcohol in her mid-30s.
RD, at 18; Tr. 234–35.3 Respondent later
began abusing zolpidem 4 and
diazepam 5 which she obtained without
a prescription either from a friend or by
going into Mexico. Tr. 235. Respondent
was arrested and convicted in 2009 for
1 The restrictions that the ALJ recommends
imposing on Respondent’s registration require her
to: (1) limit her controlled substance administering,
prescribing, and dispensing to the practice of
anesthesiology; (2) comply with the terms of the
Medical Board of California’s (MBC’s) Stipulated
Interim Order imposing restrictions on her
Registration; (3) comply with the terms of her
probation with the MBC and refrain from seeking
early termination of her probation; (4) notify DEA’s
Los Angeles Field Division of any action taken
against her license and immediately surrender her
Registration if her California medical license is
suspended or revoked; (5) remain in monitoring for
substance abuse and submit to regular urine drug
screens; (6) provide DEA with copies of all
quarterly reports issued by her practice monitor; (7)
maintain a detailed record of controlled substances
prescribed, administered, or dispensed; (8) report
all activity involving Schedule II controlled
substances to DEA on a monthly basis; (9) allow
DEA personnel to enter her registered location
during normal business hours without prior notice
or a warrant. RD, at 42–43.
2 The Agency adopts the ALJ’s summary of each
of the witnesses’ testimonies as well as the ALJ’s
assessment with respect to each of the witnesses’
credibility. RD, at 4–23.
3 The Agency agrees with the ALJ that
Respondent’s testimony was ‘‘genuine and
generally consistent,’’ despite Respondent having a
significant personal interest in the outcome of these
proceedings. RD, at 23. The ALJ found that ‘‘to the
extent that [Respondent’s testimony] differs from
the testimony of other testifying witnesses, [he
would] consider her personal interest in this case,
and [he would] give her testimony the weight that
it deserves in light of other evidence and testimony
presented during the hearing.’’ Id. The Agency
agrees with the amount of weight that the ALJ
afforded Respondent’s testimony.
4 Zolpidem is a Schedule IV controlled substance
sold under the brand name Ambien. The generic
name (zolpidem) is used in this decision.
5 Diazepam is a Schedule IV controlled substance
sold under the brand name Valium. The generic
name (diazepam) is used in this decision.
E:\FR\FM\16SEN1.SGM
16SEN1
]]>Agencies
[Federal Register Volume 89, Number 179 (Monday, September 16, 2024)]
[Notices]
[Page 75567]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-20968]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--America's DataHub Consortium
Notice is hereby given that, on June 28, 2024, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), America's DataHub Consortium
(``ADC'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing changes in
its membership. The notifications were filed for the purpose of
extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, ADACEN FEDERAL LLC, Albuquerque, NM; AT Worthy
Technology, Fairfax, VA; Brightquery, Inc., Irvine, CA; Careplots,
Inc., Malvern, PA; CAS a division of American Chemical Society,
Columbus, OH; Data Point LLC, Orange, NJ; Data Products LLC, Chicago,
IL; Generative Medical, Inc., Palo Alto, CA; K8R Applications, Inc. dba
Future Perfect Engineering, Seattle, WA; Node.Digital, Leesburg, VA;
Omnicom Consulting Group, Inc., Tarrytown, NY; Polaron Technologies,
Inc., Miamisburg, OH; Prism Lab at Cornell University, Ithaca, NY; and
Vistra Communications LLC, Lutz, FL, have been added as parties to this
venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and ADC intends to file additional
written notifications disclosing all changes in membership.
On November 11, 2021, ADC filed its original notification pursuant
to section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to section 6(b) of the Act on
December 22, 2021 (86 FR 72628).
The last notification was filed with the Department on April 4,
2024. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on June 21, 2024 (89 FR 52092).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-20968 Filed 9-13-24; 8:45 am]
BILLING CODE P
